Over-expression of Sox4 and β-catenin Is Associated with a Less Favorable Prognosis of Osteosarcoma

The purpose of this study was to examine the association of the expression of Sox4 and beta-catenin with the prognosis of osteosarcoma. A total of 108 cases of conventional osteosarcoma were involved in this study and 28 cases of osteochondroma served as controls. The expression of Sox4 and beta-catenin was detected by using immunohistochemical staining and Western blotting. The results showed that Sox4 and beta-catenin were over-expressed in 67 (62.03%) and 62 (57.41%) of 108 osteosarcoma cases, while in only 3 (10.71%) and 5 (17.86%) of 28 controls, respectively (P<0.05 for all). The expression of Sox4 and beta-catenin was associated with the distant metastasis, pathological grade and Enneking stage of patients with osteosarcoma (P<0.05 for all). The mean overall survival time and the 5-year-survival rate in osteosarcoma patients with Sox4 and beta-catenin over-expressed were significantly reduced as compared with those in Sox4 and beta-catenin low-expression group (P<0.05 for all). Cox multifactor regression analysis revealed that the distant metastasis, Enneking stage, and the expression of Sox4 and beta-catenin were independent risk factors of patients with osteosarcoma (P<0.05 for all). The findings indicated that overexpression of Sox4 and beta-catenin is associated with a poor prognosis of osteosarcoma.